Scilex Holding (SCLX) Interest Expenses (2021 - 2026)
Scilex Holding (SCLX) posted quarterly Interest Expenses of $3.8 million for Q1 2026, up 52.32% year-over-year from $2.5 million in Q1 2025, and up 8.03% on a QoQ basis from $3.5 million in Q4 2025.
Scilex Holding (SCLX) Interest Expenses (2021 - 2026) Analysis & Trends
Scilex Holding (SCLX) has reported Interest Expenses for 6 consecutive years, with $3.8 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Interest Expenses rose 52.32% year-over-year to $3.8 million; the TTM figure through Mar 2026 stood at $12.8 million (up 226.02% YoY), while the FY2025 annual figure was $11.5 million, up 483.75% from the prior year.
- Interest Expenses came in at $3.8 million for Q1 2026 at Scilex Holding, up from $3.5 million in the prior quarter.
- The five-year high for Interest Expenses was $5.3 million in Q1 2023, with the low at $7466.0 in Q1 2022.
- Average Interest Expenses over 5 years is $1.8 million, with a median of $1.0 million recorded in 2022.
- Across the five-year window, Interest Expenses jumped 70513.45% in 2023 and sank 89.93% in 2024, its largest moves.
- Year by year, Interest Expenses stood at $1.0 million in 2022, then sank by 45.34% to $551000.0 in 2023, then slumped by 48.28% to $285000.0 in 2024, then soared by 1127.37% to $3.5 million in 2025, then rose by 8.03% to $3.8 million in 2026.
- According to Business Quant data, Interest Expenses over the past three periods registered $3.8 million, $3.5 million, and $2.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | - |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 272.00 Mn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | - |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | -393.00 Mn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | - |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | 657.00 Mn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 240.00 Mn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | - |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | -343.00 Mn |
| 10 | Scilex Holding | 54.30 Mn | -95.62 Mn | 4.15 Mn | 3.78 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.78 Mn |
| Mar 31, 2026 | 3.78 Mn |
| Dec 31, 2025 | 3.50 Mn |
| Dec 31, 2025 | 3.50 Mn |
| Sep 30, 2025 | 2.80 Mn |
| Sep 30, 2025 | 2.80 Mn |
| Jun 30, 2025 | 2.68 Mn |
| Jun 30, 2025 | 2.68 Mn |
| Mar 31, 2025 | 2.48 Mn |
| Mar 31, 2025 | 2.48 Mn |
| Dec 31, 2024 | 285,000.00 |
| Dec 31, 2024 | 285,000.00 |
| Sep 30, 2024 | 576,000.00 |
| Sep 30, 2024 | 576,000.00 |
| Jun 30, 2024 | 571,000.00 |
| Jun 30, 2024 | 571,000.00 |
| Mar 31, 2024 | 531,000.00 |
| Mar 31, 2024 | 531,000.00 |
| Dec 31, 2023 | 551,000.00 |
| Dec 31, 2023 | 551,000.00 |